{
  "study_metadata": {
    "design": "double-blind",
    "species": "Homo sapiens",
    "n_total": 50,
    "country": "Iran",
    "setting": "outpatient",
    "population": "NAFLD patients",
    "inclusion_key": "NAFLD with steatosis grade ≥2, elastography >4 kPa, ALT >30/19 IU/L",
    "exclusion_key": "weight loss >10%, pregnancy, etc.",
    "mean_age": null,
    "female_pct": null,
    "diabetes_status": null,
    "primary_outcome": "other"
  },
  "intervention": {
    "agent": "resveratrol",
    "form": "capsule",
    "dose_mg_per_day": 500,
    "duration_weeks": 12,
    "cointerventions": "lifestyle modification (diet, exercise)"
  },
  "comparison": {
    "type": "placebo",
    "description": "medium‑chain triglyceride capsule"
  },
  "arms": [
    {
      "name": "resveratrol",
      "n": 25,
      "dose_mg_per_day": 500,
      "duration_weeks": 12
    },
    {
      "name": "placebo",
      "n": 25,
      "dose_mg_per_day": 0,
      "duration_weeks": 12
    }
  ],
  "outcomes_raw": [],
  "effects_by_outcome": [],
  "risk_of_bias": {
    "randomization_process": null,
    "deviations_from_intended": null,
    "missing_outcome_data": null,
    "measurement_of_outcome": null,
    "selection_of_reported_result": null,
    "overall": null
  },
  "effect": null,
  "where_found": [],
  "evidence": [
    {
      "section": "abstract",
      "page": null,
      "snippet": "In this randomized, double-blinded, controlled clinical trial, 50 NAFLD patients were supplemented with either a 500-mg resveratrol capsule or a placebo capsule for 12 weeks."
    },
    {
      "section": "methods",
      "page": null,
      "snippet": "Patients who fulfilled all eligibility criteria were randomly assigned to receive a capsule containing either 500 mg trans-resveratrol or the same amount of medium-chain triglyceride as placebo, once a day for 12 weeks."
    },
    {
      "section": "results",
      "page": null,
      "snippet": "From June 2012 to December 2012, 50 patients were enrolled and underwent randomization (Figure)."
    }
  ],
  "missing_fields": [
    "study_metadata.mean_age",
    "study_metadata.female_pct",
    "study_metadata.diabetes_status",
    "study_metadata.primary_outcome",
    "outcomes_raw",
    "effects_by_outcome",
    "risk_of_bias.randomization_process",
    "risk_of_bias.deviations_from_intended",
    "risk_of_bias.missing_outcome_data",
    "risk_of_bias.measurement_of_outcome",
    "risk_of_bias.selection_of_reported_result",
    "risk_of_bias.overall",
    "effect",
    "where_found"
  ],
  "confidence": 0.7,
  "comment": "No glycemic data reported",
  "comment_detailed": "I searched the abstract, methods, and results for glycemic outcomes such as FPG, HbA1c, or HOMA-IR. The study focused on liver enzymes and inflammatory markers in NAFLD patients, with no mention of glucose or insulin measures. Therefore, the effect of resveratrol on glycemic control cannot be determined from this article. Additional data from other trials would be needed to answer the question."
}